JAK2 and essential thrombocythemia: JAK2 V617F (Val617Phe) G>T mutation, was recently described in most patients with polycythemia Vera (PV) and in essential thrombocythemia (ET) and mutation of both JAK2 alleles has been reported in approximately 100% of the PV patients (Zhao et al., 2005).